Immuno-Oncology
Exploring the possibility of early interception in smoldering myeloma: novel agents, challenges & advances in risk stratification
Smoldering multiple myeloma (SMM) and monoclonal gammopathy of undetermined significance (MGUS) are two well-known precursor conditions to multiple myeloma, and the…
Date: 4th April 2024
Monoclonal B-cell lymphocytosis: classification, biology and exploring the possibility of early interception
Monoclonal B-cell lymphocytosis (MBL) is a condition characterized by the presence of an abnormal increase in B lymphocytes in the…
Date: 22nd March 2024
The impact of CAR-T therapy on the myeloma treatment landscape, patient selection for CAR-T & the evolving role of autoSCT
The introduction of CAR-T therapy has revolutionized the myeloma treatment landscape, offering a promising therapeutic approach for patients with relapsed/refractory…
Date: 15th March 2024
Diagnosing amyloidosis, currently available therapies & the importance of cardio-oncology
While there have been advances in the treatment and management of amyloidosis in recent years, diagnosis remains a challenge due…
Date: 7th March 2024
Addressing the importance of lymphodepletion, factors contributing to ICAHT & the cost effectiveness of CAR-T therapy
Although CAR-T cells have revolutionized the treatment of hematological malignancies, there are several important factors that must be addressed regarding…
Date: 29th February 2024
Updates with the use of CAR-T therapy in ALL: ongoing challenges, strategies to overcome resistance & future outlooks
The treatment landscape of acute lymphoblastic leukemia (ALL) has transformed with the introduction of novel immunotherapeutic agents, including CAR-T cells…
Date: 22nd February 2024
Updates in lower- and higher-risk MDS: challenges, novel agents & key clinical trials at ASH 2023
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematologic neoplasms which can be categorized into lower- and higher-risk disease (LR-MDS;…
Date: 8th February 2024
Updates, challenges and novel agents being explored in BPDCN
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive and rare hematological malignancy associated with poor prognosis. Several challenges remain…
Date: 25th January 2024
Unanswered questions regarding the sequencing of BCMA therapies, the prognostic value of CTCs & the growing role of quadruplets
The treatment and management of patients with multiple myeloma is continually evolving, giving rise to novel prognostic tools and therapeutic…
Date: 18th January 2024
ASH 2023 highlights: updates in the diagnosis and treatment of amyloidosis
In recent years, the treatment and management of light chain (AL) amyloidosis has transformed with the introduction of novel agents….
Date: 5th January 2024
MPN highlights at ASH 2023: novel agents & ongoing clinical trials in ET, PV and MF
The treatment of the BCR-ABL1-negative myeloproliferative neoplasms (MPNs), including myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET), has transformed…
Date: 22nd December 2023
iwNHL 2023 Session V: Expanding the CAR platform in NHL
The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as…
Date: 15th December 2023
